Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $5.5 million.

  • Iovance Biotherapeutics' Change in Accured Expenses fell 5670.42% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 1688.61%. This contributed to the annual value of $8.6 million for FY2024, which is 5661.98% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Change in Accured Expenses stood at $5.5 million, which was down 5670.42% from -$281000.0 recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Change in Accured Expenses high stood at $15.9 million for Q3 2023, and its period low was -$23.0 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $4.1 million (2024), whereas its average is $3.3 million.
  • Data for Iovance Biotherapeutics' Change in Accured Expenses shows a peak YoY increase of 32405.5% (in 2024) and a maximum YoY decrease of 15419.7% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Change in Accured Expenses (Quarter) stood at $9.4 million in 2023, then plummeted by 56.58% to $4.1 million in 2024, then soared by 34.65% to $5.5 million in 2025.
  • Its Change in Accured Expenses was $5.5 million in Q3 2025, compared to -$281000.0 in Q2 2025 and $2.2 million in Q1 2025.